การรักษาโรคด้วยยีน
Article Sidebar
Main Article Content
บทคัดย่อ
การรักษาโรคด้วยยีนคือการนำยีนปรกติเข้าสู่ร่างกายเพื่อแก้ไข ทดแทนหรือทำลายยีนที่ผิดปรกติที่เป็นสาเหตุ ของการเกิดโรค เช่นโรคทางพันธุกรรมและโรคติดเชื้อบางชนิด โดยมีองค์ประกอบของการรักษาคือ ยีนเพื่อการรักษา พาหะ และเซลล์เป้าหมาย หัวใจหลักของความสำเร็จของการรักษาโรคด้วยวิธีนี้อยู่ที่ความสามารถในการนำส่งยีน เพื่อการรักษาเข้าสู่เซลล์เป้าหมายซึ่งแบ่งออกเป็นสองวิธีคือ การไม่ใช้เซลล์เป็นพาหะร่วมและการใช้เซลล์เป็นพาหะ ร่วมที่เรียกว่า "genetic modified cell" ซึ่งถือว่าเป็นการผนวกกำลังการรักษาระหว่างการรักษาโรคด้วยยีนและการ รักษาโรคด้วยเซลล์ การรักษาโรคด้วยยีนมีหลายรูปแบบโดยแบ่งเป็นสามหลักการคือ การนำยีนปรกติเข้าร่างกายเพื่อ ทำหน้าที่แทน ทำลาย และเข้าจับกับโปรตีนที่ใช้ในการควบคุมการแสดงออกของยีนที่ผิดปรกตินั้นโดยมีรูปแบบย่อย ดังนี้ 1) การใช้พลาสมิด 2) แอนตี้ยีนและแอนตี้เซนส์ โอลิโกนิวคลีโอไทด์3) ไรโบไซม์ 4) ดีเอนเอไซม์ 5) ดีคอยด์ 6) แอปทาเมอร์ และ 7) อาร์เอนเอไอ การรักษาโรคด้วยยีนถูกนำมาศึกษาวิจัยในมนุษย์ตั้งแต่ ค.ศ. 1990 และปัจจุบันนี้ได้รับการอนุมัติโครงการประมาณ 100 โครงการทั่วโลกซึ่งโดยส่วนใหญ่ศึกษาวิจัยอยู่ในระยะที่ 1 ในโรคมะเร็งและโรคหัวใจและหลอดเลือด ตามลำดับ
Article Details
กรณีที่ใช้บางส่วนจากผลงานของผู้อื่น ผู้นิพนธ์ต้อง ยืนยันว่าได้รับการอนุญาต (permission) ให้ใช้ผลงานบางส่วนจากผู้นิพนธ์ต้นฉบับ (Original author) เรียบร้อยแล้ว และต้องแนบเอกสารหลักฐาน ว่าได้รับการอนุญาต (permission) ประกอบมาด้วย
เอกสารอ้างอิง
Abbott A. Italians first to use stem cells. Nature 1992;356(6369): 465.
Abdallah B, Hassan A, Benoist C, et al. A Powerful Nonviral Vector for In Vivo Gene Transfer intothe Adult Mammalian Brain: Polyethylenimine. Hum Gene Ther. 1996; 7(16): 1947-54.
Alj MB, Hellin AC, Lechanteur C, et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther.2000; 7(1): 20-26.
Anderson J, Li MJ, Palmer B, et al. Safety and Efficacy of a Lentiviral Vector Containing ThreeAnti-HIV Genesû CCR5 Ribozyme, Tat-revsiRNA, and TAR Decoy- in SCID-hu Mouse--Derived T Cells. Molecular Therapy 2007;15(6): 1182-1188.
Arbanas C. Gene therapy using adeno-associatedvirus linked to liver cancer in mice [Online].2007 Jul 26 [Cited 2011 Feb 4]. Availablefrom: http://news.wustl.edu/news/Pages/9733.aspx.
Bahner I, Kearns K, Hao QL, et al. Transduction ofHuman CD34+ Hematopoietic Progenitor Cellsby a Retroviral Vector Expressing an RRE Decoy Inhibits Human Immunodeficiency Virus Type 1 Replication in Myelomononcytic Cells Produced in Long-Term Culture. J Virol.1996; 70: 4352-4360.
Barnes K. First positive results for DNA-based flu vaccine. [Online]. [Cited 2011 Feb 10]. Available from: http://www.in-pharmatechnologist.com/content/view/print/88388
Bernstein E, Caudy AA, Hammond SM, al. Role of bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-366.
Bett Aj, Prevec L and Graham FL. Packaging Capacity and Stability of Human Adenovirus Type 5Vectors. J Virol. 1993; 67(10): 5911-5921.
Bhindi R, Fahmy RG, Lowe HC, et al. DNA Enzymes, Short Interfering RNA, and the Emerging Waveof Small-Molecule Nucleic Acid-Based Gene-Silencing Strategies. Am J Pathol.2007; 171(4): 1079-1088.
Bhindi R, Khachigian LM and Lowe HC. DNAzymes targeting the transcription factor Egr-1 reducemyocardial infarct size following ischemia-reperfusion in rats. J Thromb Haemost 2006;4: 1479-83.
Blomer U, Naldini L, Kafri T, et al. Highly Efficient and Sustained Gene Transfer in Adult Neurons witha Lentivirus Vector. J Virol. 1997; 71(9):6641-6649.
Bonini C, Bondanza A, Perna SK, et al. The Suicide Gene Therapy Challenge: How to Improve a Successful Gene Therapy Approach. Molec Ther. 2007; 15(7): 1248-1252.
Breaker RR and Joyce GF. A DNA enzymethat cleaves RNA. Chem Biol. 1994; 1(4): 223-9.
Brown AE and Catteruccia F. Toward silencing the burden of malaria: progress and prospectis for RNAi-based approaches. BioTechniques2006; 40: S38-S44.
Caley IJ, Betts MR, Irlbeck DM, et al. Humoral, Mucosal, and Cellular Immunity in Response to a Human Immunodeficiency Virus Type 1Immunogen Expressed y a Venezuelan Equine Encephalitis Virus Vaccine Vector. J Virol.1997; 71(4): 3031-3038.
Calos MP. Stability without a centromere. Proc NatlAcad Sci 1998; 95: 4084-4085.
CancerLink. Anti-bcl-2 ribozyme effective against hormone sensitive, resistant prostate cancer in culture [Online]. [Cited 2011 Feb 03]. Avail-able from: http://www.oncolink.org/resources/article.cfm.
Cavazzana-Calvo M, Hacein-Bey S, de Saint BasileG, et al. Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1Disease. Science 2000; 288(5466):669-672.
Chaloin L, Lehmann MJ, SczakielG, et al. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication ofHIV-1. Nucleic Acids Res. 2002; 30(18):4001-4008.
Chang MY, Won SJ and Liu HS. A ribozyme specifically suppress transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines. J Cancer Res Clin Oncol. 1997;123: 91-99.
Chang SJ, Chen WC, Yang JC, et al. [Construction of adenovirus anti-vascular endothelial growth factor hairpin ribozyme and its inhibition of growth of colorectal cancer HT-29 cells]. Ai Zheng 2009; 28(4): 373-8.
Charoensit P, Kawakami S, Higuchi Y, et al. Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Ther. 2010; 17: 512-522.
Cheng J, Luo J, Zhang X, et al. Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc specific ribozyme. Cancer Gene Ther.2000; 7(3): 407-412.
Cheng TL, Chang WW, Su IJ, et al. Therapeutic inhibition of hepatitis B virus surface antigen expression by RNA interference. Biochem Biophy Res Comm. 2005; 336: 820-830.
Chen Y, Cheng G and Mahato RI. RNAi for Treating Hepatitis B Viral Infection. Pharmaceutical Res.2008; 25(1): 72-86.
Chuang YC, Chou AK, Wu PC, et al. Gene Therapy for Bladder Pain With Gene Gun Particle Encoding Pro-Opiomelanocortin cDNA. J Uro.2003; 170: 2044-2048.
Chou J, Kern ER, Roizman W, et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250(4985):1262-1266.
Chou SH, Chin KH and Wang AHJ. DNA aptamers as potential anti-HIV agents. TRENDS in Biochemical Sciences 2005; 30(5): 231-234.
Ciafre SA, Niola F, Wannenes F, et al. An Anti-VEGF Ribozyme Embedded within the Adenoviral VAI Sequence Inhibits Glioblastoma Cell Angiogenic Potential in vitro. J Vasc Res 2004; 41: 220-228.
Cline MJ, Stang H, Mercola K, et al. Gene transfer in intact animals. Nature 1980; 284: 422-425.
Dass CR, Choong PFM, Khanchigian LM. DNAzyme technology and cancer therapy: cleave and letdie. Molec Cancer Ther. 2008; 7: 243-251.
Davis BR, Brown DB, Prokopishyn NL, et al. Micro-injection-mediated hematopoietic stem cell gene therapy. Curr Opin Mol Ther. 2000;2(4): 412-9.
Davis NL, Brown KW and Johnston RE. A viral vac-cine vector that expresses for eign genes in lymph nodes and protects against mucosal challenge. J Virol. 1996; 70(6): 3781-3787.
Davis NL, Willis LV, Smith JF, et al. In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant. Virology 1989; 171:189-204.
de Feyter R and Li P. Technology evaluation: HIV ribozyme gene therapy, Gene Shears Pty Ltd. Curr Opin Mol Ther. 2000; 2(3): 332-5.
Denny WA. Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). J Biolmed and Biotech. 2003; 2003:1:48-70.
de Soultrait VR, Lozach PY, Altmeryer R, et al. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti- integrase agents. J Mol Biol 2002; 324(2): 195-203.
Dias N and Stein CA. Antisense Oligonucleotides: Basic Concepts and Mechanisms. Molec Cancer Therapeu. 2002; 1: 347-355.
DiFiglia M, Sena-Esteves M, Chase K, et al. Thera-peutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. PNAS 2007;104(43): 17204-17209.
Donnelly JJ, Wahren B and Liu MA. DNA Vaccines: Progress and Challenges. J Immunol. 2005;175: 633-639.
Dong JY, Fan PD and Frizzell RA. capacity of recom-binant adeno-associated virus. Hum Gen Ther.1996; 7(17): 2101-12.
Dufes C, Uchegbu IF and Schatzlein AG. Dendrimersin gene delivery. Adv Drug Deliv Rev. 2005;57(15):2177-202.
Edelstein ML, Abedi MR and Wixon J. Gene therapyclinical trials worldwide to 2007-an update. J Gene Med 2007; 9: 833-842.
Elbashir SM, Lendeckel W and Tuschl T. RNA interference is mediated by 21-and 22-nucle-otide RNAs. Genes Development. 2001; 15:188-200.
Elbashir SM, Martinez J, Patkaniowska A, et al. Func-tional anatomy of siRNAs for mediating efficient RNA in Drosophilla melanogaster embryo lysate. EMBO J 2001; 20: 6877-6888.
Ellington AD and Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-822.
Fernandes JC, Tiera MJ and Winnik FM. Chitosan Nanoparticles for Non-Viral Gene Therapy. Am Chem Soci. 2006; 934: 177-200.
Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
Franco LH, Wowk PF, Silva CL, et al. A DNA vaccine against tuberculosis based on the 65 kDa heat-shock protein differentially activates human macrophages and dendritic cells. Genetic Vaccines and Therapy 2008; 6: 1-11.
Friedmann T. Progress Toward Human Gene Therapy. Science 1989; 244: 1275-1281.
Friedmann T and Roblin R. Gene Therapy for Human Genetic Disease? Science 1972; 175(4025): 949-955.
Fukushima A, Fukuda N, Ueno T, et al. Development of a Chimeric DNA-RNA Hammerhead Ribozyme Targeting SARS Virus. Intervirology2009; 52: 92-99.
Gaspar VM, Sousa F, Queiroz JA, et al. Formulation of chitosan-TPP-pDNA nanocapsules for gene therapy applications. Nanotechnology 2011;22(1): 015101.GeneTherapyReview [Cell & Gene Therapy Forum2011]. Plasmid DNA Transfection [Online].2009 Dec 29 [Cited 2011 Mar 1]. Available from: http://www.genetherapyreview.com/gene-therapy-education/gene-transfer-vectors/2/147-dna-transfection.htmlGerstein
MB, Bruce C, Rozowsky JS, et al. What is a gene, post-ENCODE? History and updated definition. Genome Res. 2007; 17: 669-681.
Gu JL, Veerapanane D, Rossi J, et al. Ribozyme-Mediated Inhibition of Expression of Leuko-cyte-type 12-Lipoxygenase in Porcine Aotic Vascular Smooth Muscle Cells. Circ Res.1995; 77: 14-20.
Hammond G and Simard MJ. Argonaute proteins key players in RNA silencing. Nature Review Mol Cell Biol. 2008; 9: 22-32.
Hammond SM, Bernstein E, Beach D, et al. An RNA-directed nuclease mediates posttranscriptional gene silencing in Drosophila cells. Nature2000; 404: 293-296.
He P, Zhu D, Hu JJ, et al. pcDNA3.1(-)-mediated targeting of HER-2 suppresses breast cancer tumor growth. Mol Biol Rep. 2009; 37(3):1597-1604.
Held DM, Kissel JD, Patterson JT, et al. HIV- 1 inactivation by nucleic acid aptamers. Frontiers in Bioscience 2006; 11: 89-112.
Hu WY, Fukuda N, Kotani M, et al. Adenovirus-Mediated Transfer of Ribozyme Targeting Platelet-Derived Growth Factor A-Chain mRNA Inhibits Growth of Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats. J Cardio Pharmaco. 2002; 39(6): 858-865.
Huang F, Hua X, Yang S, et al. Effective inhibition of hepatitis E virus replication in A549 cells and piglets by RNA interference (RNAi) targeting RNA-dependent RNA polymerase. Antiviral Res. 2009; 83: 274- 281.
Hudry E, Van DD, Kulik W, et al. Adeno- associated Virus Gene Therapy With Cholesterol 24-Hy-droxylase Reduces the Amyloid Pathology Before or After the Onset of Amyloid P; aques in Mouse Models of Alzheimer’s Disease. The American Society of Gene & Cell Therapy2010; 18(1): 44-53.
Human Genome Project Information. Gene Therapy[Online]. [Cited 2010 Sep 7]. Available from: http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetherapy.shtml.
Hui EKW, Yap EM, An DS, et al. Inhibition of influenza virus matrix (M1) protein expression and virus replication by U6 promoter driven and lentivirus-mediated delivery of siRNA. J General Virol. 2004; 85: 1877-1884.
Isaka Y, Nakamura H, Mizui M, et al. DNAzyme for TGF-? suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kindey Inter. 2004; 66: 586-590.
Isamu L, Kanzaki B, Ornelas SS, et al. RNA interference and HIV-1 infection. Rev. Med. Virol.2008; 18: 5-18.
Jarald E, Edwin S, Dubey P, et al. Nucleic acid drugs: a novel approach. African J Biotech. 2004;3(12): 662-666.
Jeong S, Han SR, Lee YJ, et al. Identification of RNA Aptamer Specific to Mutant KRAS Protein. Oligonucleotides 2010; 20(3): 155-161.
Jeon SH, Kayhan B, Yedidia TB, et al. A DNA Aptamer Prevents Influenza Infection by Blocking the Receptor Binding Region of the Viral Hemagglutinin. J Biol Chem. 2004; 279(46):48410-48419.
Jeong JH, Kim SH, Lee M, et al. Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice. J Control Release. 2010; 143(1): 88-94.
Josef MF, Snyder EY and Loring JF. Gene therapy: can neural stem cells deliver? Nature reviews neuroscience 2006; 7: 75-84.
Juliano R, Alam R, Dixit V, et al. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res.2008; 36(12): 4158-4171.
Kay MA, Glorioso JC and Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature Medicine 2001; 7: 33-40.
Kim SH, Jeong JH, Ou M, et al. Cardiomyocytetargeted siRNA delivery by prostaglandinE2-Fas siRNA polyplexes formulated with reducible poly) amido amine) for preventing cardiomyocyte apoptosis. Biomaterials 2008;29(33): 4439-4446.
Kim SI, Shin D, Lee H, et al. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol. 2009; 50(3): 479-488.
Kim VN, Mitrophanous K, Kingsman SM, et al. Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type1. J Virol. 1998; 72(1): 811-816.
Kolb G, Reigadas S, Castanotto D, et al. Endogenous Expression of an Anti-TAR Aptamer ReducesHIV-1 Replication. RNA Biol. 2006; 3(4):150-156.
Kotin RM, Siniscalco M, Samulski RJ, et al. Site-spe-cific integration by adeno-associated virus. Proc Natl Acad Sci. 1990; 87: 2211-2215.
Kumar P, Sood V, Vyas R, et al. Potent inhibition of influenza virus replication with novel siRNA-chimeric-ribozyme constructs. Antiviral Res.2010; 87(2): 204-212.
Lazarev VN, Shmarov MM, Zakhartchouk AN, et al. Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. Antiviral Res. 1999; 42(1): 47-57.
Leachman SA, Hickerson RP, Hull PR, et al. Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenital. J Dermatol Sci. 2008; 1749: 1-7.
Leirdal M and Sioud M. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer]. Tidsskr Nor Laegeforen.2002; 122(2): 178-82.
Lewis PF and Emerman M. Passage through MitosisIs Required for Oncoretroviruses Not for the Human Immunodeficiency Virus. J Virol. 1994:68(1): 510-516.
Li S and Huang L. Nonviral gene therapy: promises and challenges. Gene Ther. 2000; 7: 31-34.
Liu Y, Wang Y, Wan C, et al. The Role of mPer1 in Morphine Dependence in Mice.Neuroscience2005; 130(2): 383-388.
Lisovyy OO, Dosenko VE, Nagibin VS, et al. Cardiopro tective effect of 5-lipoxygenase gene (ALOX5) silencing in ischemia-reperfusion. Acta Biochimica Polonica 2009; 56(4): 687-694.
Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science2004; 305: 1437-1441.
Lollo CP, Banaszczyk MG, Mullen PM, et al. Poly-L-Lysine-Based Gene Delivery Systems Synthesis, Purification, and Application. Gene Therapy Protocols 2002; 69: 1-13.
Lowenstein PR, Morrison EE, Bain D, et al. Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins inpostmitotic polarized cortical neurons and glialcells in vitro. Neurocience 1994; 60(4):1059-77.
Luo X, Cai H, Ni J, et al. c-Jun DNAzymes Inhibit Myocardial Inflammation, ROS Generation, Infarct Size, and Improve Cardiac Fusion After Ischemia-Reperfusion Injury. Arterioscler Thromb Vasc Biol 2009; 29: 1836-1842.
Manfredsson FP, Lewin AS and Mandel RJ. RNA knockdown as a potential therapeutic strategyin Parkinsonûs disease. Gene Ther. 2006; 13:517-524.
Martines J, Patkaniowska A, Urlaub H, et al. Single-stranded antisense siRNAs guide target RNA cleavage i RNAi. Cell 2002; 110:563-574.
Marz P, Probst A, Lag S, et al. Ataxin-10, the Spinocerebellar Ataxia Type 10 Neurodegenerative Disorder Protein, Is Essential for Survival of Cerebellar Neurons. J Biol Chem. 2004;279(34): 35542-35550.
McShan WM, Rossen RD, Laughter AH, et al. Inhibition of Transcription of HIV-1 in Infected Human Cells by Oligodeoxynucletides Designed to Form DNA Triple Helices. J Biological Chem.1992; 267: 5712-5721.
Miller VM, Gouvion CM, Davidson BL, et al. Targeting Alzheimer’s disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res. 2004: 32(2):661-668.
Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine2009; 15: 285-292.
Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binging site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci 1995; 92: 5855-5859.
Morsy MA, Gu MC, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. 1998; 95: 7866-7871.
Morishita R, Higaki J, Tomita N, et al. Application of Transcription Factor “Decoy” Strategy as Means of Gene Therapy and Study of Gene Expression in Cardiovascular Disease. Circ Res. 1998; 82: 1023-1028.
Mulamba G, Hu A, Azad RF, et al. Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorthioate Oligonucleotide Fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 1998; 42(4): 971-973.
Nakagami H, Tomita N, Kaneda Y, et al. Anti-oxidantgene therapy by NF kappa B decoy oligonucleotide. Curr Pharm Biotechnol. 2006; 7(2): 95-100.
Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259): 263-7.
Naxin W, Watkins SC, Schaffer PA, et al. Prolonged Gene Expression and Cell Survival after Infection by a Hepes Simplex Virus Mutant Defective in the Immediate- Early Genes Encoding ICP4, ICP27, and ICP22. J Virol.1996; 70(9): 6358-6369.
Neff CP, Zhou J, Remling L, et al. An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+T Cell Decline in Humarized Mice. Sci Transl Med. 2011;3(66): 66ra6.
Nguyen MD, Cinman N, Yen J, et al. DNA-based vaccination for the treatment of food allergy. Allergy 2001; 56: 127-130.
Pai SI, Lin Y-Y, Macaes B, et al. Prospects of RNA interference therapy for cancer. Gene Ther.2006; 13: 464-477.
Paleos CM, Tziveleka LA, Sideratou Z, et al. Gene delivery using functional dendritic polymers. Expert Opin Drug Deliv. 2009; 6(1): 27-38.
Parry TJ, Cushman C, Gallegos AM, et al. Bioactivity of anti-angiogenic ribozymes targeting Flt-1and KDR mRNA. Nucleic Acids Res. 1999;27(13): 2569-2577.
Patil SD, Rhodes DG and Burgess DJ. DNA-based Therapeutics and DNA Delivery Systems: A Comprehensive Review. AAPS J. 2005; 7(1): E61-E77.
Pawlotsky JM, Chevaliez S and McHutchison JG. The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies. Gastroenterology 2007; 132: 1979-1998.
Pearson H. Genetics: What is a gene? Nature 2006;441: 398-401.
Pearson S, Jia H and Kandachi K. China approves first gene therapy. Nature Biotechnology 2004;22: 3-4.
Poller W, Hajjar R, Schultheiss HP, et al. Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc Res 2010; 86: 353-364.
Ponnazhagan S, Curiel DT, Shaw DR, et al. Adeno-associated Virus for Cancer Gene Therapy. Cancer Res 2001; 61: 6313-6321.
Prevent IV Investigator. Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery. JAMA 2005; 294(19): 2446-2454.
Rath P, Shi H, Maruniak JA, et al. Stem Cells as Vectors to Deliver HSV/tk Gene Therapy for Malignant Gliomas. Curr Stem Cell Res Therapy2009; 4: 44-49.
Rey S, Lee K, Wang CJ, et al. Synergistic effect ofHIF-1alpha gene therapy and HIF-1-activatedbone marrow-derived angiogenic cells in a mouse model of limb ischemia. PNAS 2009; 106(48): 20399-20404.
Richards JL, Seward GK, Wang YH, et al. Turnign the10-23 DNAzyme On and Off with Light. Chem Bio Chem 2010; 11: 320-324.
Rigden JE, Ely JA, Macpherson JL, et al. The Use of Ribozyme Gene Therapy for the Inhibition of HIV Replication and its Pathogenic Sequelae. Curr Issues Mol. Biol. 2000; 2(2): 61-69.
Roe T, Reynolds TC and Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 1993; 12(5): 2099-2108.
Rondinone CM. Therapeutic potential of RNAi in metabolic diseases. Bio Techniques 2006; 40: S31-S36.
Rosenberg S, Aebersold P, Cornetta K, et al. Gene transfer into humans-Immunotherapy of patients with advanced melanoma, using tumor-infiltration lymphocytes modified by retroviral gene transduction. N Engl J Med1990; 323(9): 570-578.
Rose JA, Berns KI, Hoggan DM, et al. Evidence for a single-stranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA. Microbiol. 1969; 64:863-869.
Rossi JJ. RNAi as a treatment for HIV-1 infection. Bio Techniques 2006; 40: S25-S29.
Roth JA and Cristiano RJ. Gene Therapy for Cancer: What Have We Done and Where Are We Going? J Natl Cancer Inst. 1997; 89(1):21-39.
Samulski RJ, Xhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 1991; 10(12): 3941-3950.
Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. 1998; 18: 180-183.
Sharma R, Khajuria R, Sharma CL, et al. Gene Therapy: Current Concepts. JK Science 2004;6(2): 62-66.
Singer O, Marr RA, Rockenstein E, et al. TargetingBACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nature Neuroscience 2005; 8: 1343-1349.
Singh SK and Gaur RK. Progress towards Therapeutic Application of RNA Interference for HIV Infection. Biodrugs 2009; 23(5): 269-276.
Song DP, Lin JS, Sun XM, et al. [Hammerheadribozyme against human telomerase catalyticsubunit (hTERT) induced apoptosis of livercancer cells]. Zhonghua Gan Zang Bing Za Zhi.2004; 12(10): 616-9.
Song H, Zhang D, Cheng F, et al. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep. 2009; 36: 2153-2163.
Spoerri PE, Afzal A, Li CS, et al. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Mol Vis. 2006; 12: 32-42.
Stephenson ML and Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific
oligodeoxyribonucleotide. Proc. Natl. Acad. Sci1978; 75(1): 285-288.
Stull RA and Jr. Szoka FC. Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects. Pharm Res. 1995; 12(4): 465-483.
Su JZ, Fukuda N, Hu WY, et al. Ribozyme to Human TGF-?1 mRNA Inhibits the Proliferation of Human Vascular Smooth Muscle Cells. Biochem Biophy Res Comm. 2000; 278(2):401-407.
Subramanya S, Kim SS, Manjunath N, et al. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther. 2010; 10(2): 201-13.
Sui HY, Zhao GY, Huang JD, et al. Small Interfering RNA Targeting M2 Gene Induces Effective and Long Term Inhibition of Influenza A Virus Replication. PloS One 2009; 4(5): e5671.
Sun X and Zhang N. Cationic polymer optimization for efficient gne delivery. Mini Rev Med Chem.2010; 10(2): 108-25.
Tang XB, Hobom G and Luo D. Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J Med Virol. 1994; 42(4): 385-95.
Tang Y, Ge Y-Z and Yin JQ. Exploring in vitro roles of siRNA in cardiovascular disease. Acta Pharmacol Sin. 2007; 28(1): 1-9.
Templeton NS. Cationic Liposome-mediated Gene Delivery In vivo. Bioscience Reports 2002; 22(2): 283-295.
The Journal of Gene Medicine. Gene Therapy Clinical Trials Worlwide [Online]. [Cited 2011 Mar 5]. Available from: http://www.wiley.com/legacy/wileychi/genmed/clinical/.
The National Institute of Health resource for stem cell research. 11. Use of Genetically Modified Stem Cells in Experimental Gene Therapies [StemCell Informaiton] [Online]. [Cited 2010 Sep 7]. Available from: http://stemcells.nih.gov/info/scireport/chapter11.asp.
The National Institutes of Health Office of Technology Transfer, US Department of Health and Human Services. FDA Approved Products with Technologies from the NIH Intramural Research Program [Online]. [cited 2011 Mar 5]. Avail-able from:http://www.ott.nih.gov/about_nih/fda_approved_products.aspx.
Traversari C and Bordignon C. Antigen transduced T cells used as a delivery system for antigens. U.S. Patent Application Publication 2008; US2008/0286305 A1: 1-16.
Trang P, Lee J, Kilani AF, et al. Effective inhibition of herpes simplex virus 1 gene expression and growth by engineered R Nase P ribozyme. Nucleic Acids Res 2001; 29(24): 5071-5078.
Unwalla HJ and Rossi J. A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle. Virol J. 2010; 7: 33.
U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Industry: Validation of Growth-Based Rapid Microbiological Methods for Sterility Testing of Cellular and Gene Therapy Products. FDA U.S. Food and Drug Administration. Feb 2008: 1-12.
U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications(INDs). FDA U.S. Food and Drug Administration. Apr 2008: 1-41. U.S.
Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Indus-try: Potency Tests for Cellular and Gene Therapy Products. FDA U.S. Food and Drug Administration. Oct 2008: 1-15.
Vorburger SA and Hunt KK. Adenoviral Gene Therapy. Oncologist 2002; 7: 46-59. Walther W and Stein U. Viral Vectors for Gene Transfer. Drugs 2000; 60(2): 249-271.
Wang CX, Lu YQ, Chen LH, et al. Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus. Virol J. 2010; 7: 61.
Wang Hi, Chen XP and Qiu FZ. Overcoming multi-drug resistance by anti-MDR1 ribozyme. World J Gastroenterol. 2003; 9(7): 1444-1449.
Watson JD and Crick FH. Molecular structure of nucleic acids. Nature 1953;171: 737-738.
Weizsacker FV, Blum HE and Wands JR. Hammer-head Ribozyme-Mediated Cleavage of Hepatitis B Virus RNA. Medthods in Molecular Medicine 1998; 11: 111-117.
Welch PJ, Yel S and Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diag Virol. 1998; 10: 163-171.
Wells DJ. Gene Therapy Progress and Prospects: Electroporation and other physical methods. Gene Ther. 2004; 11: 1363-1369.
Wikepedia. DNA vaccination [Online]. [Cited 2010 Apr09]. Available from: http://en.wikepedia.org/wiki/DNA_vaccination.Wikepedia. Plasmid [Online]. [Cited 2011 Feb 04]. Available from: http://en.wikepedia.org/wiki/Plasmid.
Wong JP, Christopher ME, Salaza AM, et al. Broad-spectrum and virus-specific nucleic acid-based antivirals against influencza. Front Biosci (Schol Ed). 2010; 2: 791-800.
Xia H, Mao Q, Eliason SL, et al. RNAi Suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature Med.2004; 10(8): 816-820.
Xiong C, Levis R, Shen P, et al. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 1989;243(4895): 1188-1191.
Yamagata M, Kawano T, Shiba K, et al. Structural advantage of dendritic poly (L- lysine) for gene delivery into cells. Bioorg & Med Chem. 2007;15(1): 526-532.
Yamamoto Y, Matsuura T, Narazaki G, et al. Synergistic effect of autologous cell and hepatocyte growth factor gene therapy for neovascularization in a murine model of hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2009; 297: H1329-H1336.
Yang NS and Sun WH. Gene gun and other non-viral approaches for cancer gene therapy. Nature Medicine 1995; 1: 481-483.
Yu SH, Wang TH and Au LC. Specific repression of mutant K-RAS by 10-23 DNAzyme: Sensi-tizing cancer cell to anto-cancer therapies. Biochem Biophy Res Comm. 2009; 378(2):230-234.
Zhang et al. Small-molecule nucleotide aptamer for hepatitis C virus, preparation method and use ther of. United States Patent Application Publication 2010; US 2010/0184837 A1.
Zhou H, Jin M, Yu Z, et al. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replica-tion in cells and mice. Antiviral Res. 2007;76: 186-193.
Zhou J, Li H, Li S, et al. Novel Dual Inhibitory Function Aptamer-siRNA Delivery System for HIV-1 Therapy. Molecular Therapy 2008;16(8): 1481-1489.
